Alva EC

Idioma: Inglés [English version]
Referencias bibliográficas: 25
Paginas: 141-144
Archivo PDF: 177.05 Kb.

RESUMEN

Durante los meses iniciales de la pandemia de COVID-19, se pensaba que la enfermedad en los niños era benigna y poco frecuente, a partir de marzo ha surgido el síndrome inflamatorio multisistémico (MIS-C) en niños asociado con la pandemia como una enfermedad grave. Tiene similitudes con la enfermedad de Kawasaki, aunque también importantes diferencias, como mayor edad, adicionales síntomas abdominales, escasos respiratorios, incremento en la severidad de la inflamación, falla cardiaca y choque. Especulamos en esta revisión: 1) si MIS-C es una acelerada forma de Kawasaki, 2) si se trata de una entidad diferente, o 3) simplemente MIS-C es una variante grave de COVID-19 en niños. La presencia del síndrome inflamatorio multisistémico en niños asociado con COVID-19 (MIS-C o PIMS-TS), en buena parte del mundo, debe alertar a la comunidad médica en los países en los que por el momento no se ha reconocido.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109 (6): 1088-1095.

2. Li X, Xu S, Yu M et al. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. J Allergy Clin Immunol. 2020; 146 (1): 110-118.

3. Guan WJ, Ni ZY, Hu Y et al. China medical treatment expert group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-1720.

4. Simonnet A, Chetboun M, Poissy J et al. LICORN and the Lille COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020; 28 (7): 1195-1199.

5. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062.

6. Guzik TJ, Mohiddin SA, Dimarco A et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020: cvaa106. doi: 10.1093/cvr/cvaa106.

7. Whittaker E, Bamford A, Kenny J et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020. doi: 10.1001/jama.2020.10369.

8. Health alert #16: updated reporting for multisystem inflammatory syndrome in children associated with COVID-19. 2020. Available in: https://www1.nyc.gov/assets/doh/downloads/pdf/han/advisory/2020/covid-19-providers-mis-c.pdf

9. Verdoni L, Mazza A, Gervasoni A et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020; 395 (10239):1 771-1778.

10. Cabrero-Hernández M, García-Salido A, Leoz-Gordillo I et al. Severe SARS-CoV-2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in Spain. Pediatr Infect Dis J. 2020; 39 (8): e195-e198. doi: 10.1097/INF.0000000000002777.

11. Chiotos K, Bassiri H, Behrens EM et al. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. J Pediatric Infect Dis Soc. 2020; 9 (3): 393-398.

12. Belhadjer Z, Méot M, Bajolle F et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020. doi: 10.1161/CIRCULATIONAHA.120.048360.

13. Toubiana J, Poirault C, Corsia A et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020; 369: m2094. doi: 10.1136/bmj.m2094.

14. Newburger JW, Takahashi M, Burns C. Kawasaki disease. J Am Coll Cardiol. 2016; 67: 1738-1749.

15. Riollano-Cruz M, Akkoyun E, Briceno-Brito E et al. Multisystem inflammatory syndrome in children related to COVID-19: A New York City experience. J Med Virol. 2020: 10.1002/jmv.26224.

16. Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel). 2020; 7 (7): 69. doi: 10.3390/children7070069.

17. Capone CA, Subramony A, Sweberg T et al. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory disease of childhood (MIS-C) associated with SARS-CoV-2 infection. J Pediatr. 2020; 224: 141-145. doi: 10.1016/j.jpeds.2020.06.044.

18. Kaushik S, Aydin SI, Derespina KR et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from new york city. J Pediatr. 2020; 224: 24-29.

19. Saguil A, Fargo M, Grogan S. Diagnosis and management of Kawasaki disease. Am Fam Physician. 2015; 91 (6): 365-371.

20. Sundel RP. Kawasaki disease. Rheum Dis Clin North Am. 2015; 41 (1): 63-73, viii.

21. Dusser P, Koné-Paut I. IL-1 inhibition may have an important role in treating refractory Kawasaki disease. Front Pharmacol. 2017; 8: 163.

22. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: Scientific brief. 15 May 2020. WHO/2019-nCoV/Sci_Brief/Multisystem_Syndrome_Children/2020.1

23. Dirección General de Información en Salud (DGIS). Secretaría de Salud. Disponible en: http://www.dgis.salud.gob.mx/contenidos/basededatos/BDCubos.html.

24. Alva-Espinoza C, Díaz-Aranzo A, Mojarro-Ríos TA et al. Enfermedad de Kawasaki diagnóstico ecocardiográfico de los aneurismas coronarios. Informe de dos casos. Arch Inst Cardiol Mex. 1995; 65: 73-75.

25. Sotelo-Cruz N. Revisión de la enfermedad de Kawasaki en México, desde la perspectiva de las publicaciones médicas (enero de 1977 a mayo de 2012). Arch Cardiol Mex. 2013; 83 (3): 214-222.